Evidence map›Paper›PMID 39613925›Full record

ArticleEJNMMI reports2024

Inter- and intra-tumoral heterogeneity on [

Camila Gadens Zamboni, Ayca Dundar, Sanchay Jain, Marc Kruzer, Bradley T Loeffler, Stephen A Graves, Janet H Pollard, Sarah L Mott, Joseph S Dillon, Michael M Graham and 2 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in EJNMMI reports, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Immune Checkpoint Blockade Enhances the Abscopal Effect of [European journal of nuclear medicine and molecular imaging · 2026
    Article
  2. Article
  3. Article
  4. Review
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Camila Gadens Zamboni *Division of Nuclear Medicine, Department of Radiology-Room 3820-AJPP, University of Iowa Carver College of Medicine, 200 Hawkins Drive, Iowa City, IA, 52242, USA.
Ayca Dundar *Division of Nuclear Medicine, Department of Radiology-Room 3820-AJPP, University of Iowa Carver College of Medicine, 200 Hawkins Drive, Iowa City, IA, 52242, USA.
Sanchay JainDivision of Nuclear Medicine, Department of Radiology-Room 3820-AJPP, University of Iowa Carver College of Medicine, 200 Hawkins Drive, Iowa City, IA, 52242, USA.
Marc KruzerMIM Software Inc, Beachwood, OH, USA.
Bradley T LoefflerBiostatistics Core, Holden Comprehensive Cancer Center, Iowa City, IA, USA.
Stephen A GravesDivision of Nuclear Medicine, Department of Radiology-Room 3820-AJPP, University of Iowa Carver College of Medicine, 200 Hawkins Drive, Iowa City, IA, 52242, USA.
Janet H PollardDivision of Nuclear Medicine, Department of Radiology-Room 3820-AJPP, University of Iowa Carver College of Medicine, 200 Hawkins Drive, Iowa City, IA, 52242, USA.
Sarah L MottBiostatistics Core, Holden Comprehensive Cancer Center, Iowa City, IA, USA.
Joseph S DillonDepartment of Medicine-Hematology/Oncology, University of Iowa Carver College of Medicine, Iowa City, IA, USA.
Michael M GrahamDivision of Nuclear Medicine, Department of Radiology-Room 3820-AJPP, University of Iowa Carver College of Medicine, 200 Hawkins Drive, Iowa City, IA, 52242, USA.
Yusuf MendaDivision of Nuclear Medicine, Department of Radiology-Room 3820-AJPP, University of Iowa Carver College of Medicine, 200 Hawkins Drive, Iowa City, IA, 52242, USA.
Ahmad ShariftabriziDivision of Nuclear Medicine, Department of Radiology-Room 3820-AJPP, University of Iowa Carver College of Medicine, 200 Hawkins Drive, Iowa City, IA, 52242, USA. ashariftabrizi@healthcare.uiowa.edu.ORCID http://orcid.org/0000-0003-2397-6914

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundIndices of tumor heterogeneity on somatostatin receptor PET/CT scans may potentially serve as predictive biomarkers of treatment efficacy in neuroendocrine tumor (NET) patients undergoing [

methodsNET patients who underwent [

resultsEighty patients with a mean age of 65.1 years were included, with most (71.3%) completing 4 cycles of PRRT. Median TTP was 19.1 months, and OS at 60 months was 50%. A large degree of variability between patients was evidenced for imaging features related to somatostatin receptor expression. On multivariable analysis, total receptor expression and mean liver-corrected SUVmean were selected for 24-month TTP. The model was not able to significantly predict progression (C-statistic = 0.58, 95% CI 0.50-0.62). Total receptor expression and mean skewness were selected for OS. The resulting model was able to significantly predict death (C-statistic = 0.62, 95% CI 0.53-0.67), but the predictive ability was limited, as evidenced by the low C-statistic.

conclusionsOur exploratory analysis provides preliminary results showing that imaging indices of inter- and intra-tumor heterogeneity from pretreatment PET/CT images may potentially predict treatment efficacy in NET patients undergoing [

Identifiers

PMID39613925
PMCPMC11607192

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.